Supply chain focus dependent safety stock placement

Increasing globalization, growing product range diversity, and rising consumer awareness are making markets highly competitive, forcing supply chains to adapt constantly to different stimuli. Growing competition between supply chains (as well as players within them) is also warranting a priority for overall supply chain performance over the goals of individual players. It is now well established in the literature that, among the many order winners, both overall supply chain cost and responsiveness (i.e., supply chain lead time) are the most significant determinants of supply chain competitiveness. The literature, however, mostly focuses on supply chain cost minimization with rather simplistic treatment of responsiveness. By introducing the concept of a coefficient of inverse responsiveness (CIR), we facilitate efficient introduction of responsiveness related costs into the scheme of supply chain (SC) performance evaluation and/or optimization. Thus, our model aids supply chain managers in achieving better strategic fit between individual business unit strategies and overall supply chain requirements in terms of cost efficiency and responsiveness. In particular, it aids in strategic placement of safety stocks at different stages in the supply chain. Our model also offers managerial insights that help improve our intuitions into supply chain dynamics. The model is more suited for strategic SC alignment, for example, when dealing with product changeovers or introduction of new product, rather than for operational control.     

Reduced graphene oxide wrapped sulfur nanocomposite as cathode material for lithium sulfur battery

Sulfur has been investigated as an active electrode material for secondary batteries due to theoretically specific capacity compared to the lithium-ion battery. In the present study, reduced graphene oxide (RGO) sheets wrapped Sulfur nanocomposite (S-RGO) synthesized by hydrothermal method and confirmed the wrapping of RGO sheets on Sulfur nanoparticles by various analytical techniques. The synthesized S-RGO nanocomposite demonstrated improved interaction of sulfur nanoparticles with RGO which is confirmed through XPS analysis. The synthesized S-RGO resulted in significantly improved reversible specific capacity and higher rate capability (823 mAh/g at 0.1C, 400 mAh/g at 1C) with 77 wt% of sulfur loading amount on the cathode of the Li–S battery. Therefore, the present study opens up new insights into sustainable development in the field of Li–S battery energy storage applications.     

Supply chain focus dependent sensitivity of the point of product differentiation

Customer preferences for variety in the product(s) with improved customer service and lower prices are forcing the supply chains to overhaul the current practices from design to operational level. Postponement or delayed differentiation of the products is one such strategy, primarily deployed in mass customisation settings. Life cycles are shrinking not only for individual products but for product families as well. In this context, supply chain responsiveness becomes one of the crucial factors that need to be effectively managed to succeed in the present day competitive markets. Our model, that considers inventory costs and the supply chain responsiveness costs would aid a supply chain manager to make informed decisions with regard to the ideal location for the point of differentiation (POD), while striking the right balance between holding costs and the supply chain responsiveness costs. We also make use of a dimensionless parameter called the ‘coefficient of inverse responsiveness’ that not only facilitates the introduction of responsiveness related costs into the model but also improves the scalability and simplifies the analysis and interpretation of the results. Based on the strategic model developed, we offer some context-specific counter-intuitive managerial insights with respect to the sensitivity of the location of the POD in a supply chain.     

Design and Synthesis of DNA‐Interactive β‐Carboline–Oxindole Hybrids as Cytotoxic and Apoptosis‐Inducing Agents

A new series of (E)‐3‐[(1‐aryl‐9H‐pyrido[3,4‐b]indol‐3‐yl)methylene]indolin‐2‐one hybrids were synthesized and evaluated for their in vitro cytotoxic activity against a panel of selected human cancer cell lines, namely, HCT‐15, HCT‐116, A549, NCI‐H460, and MCF‐7, including HFL. Among the tested compounds, (E)‐1‐benzyl‐5‐bromo‐3‐{[1‐(2,5‐dimethoxyphenyl)‐9H‐pyrido[3,4‐b]indol‐3‐yl]methylene}indolin‐2‐one ( 10 s ) showed potent cytotoxicity against HCT‐15 cancer cells with an IC₅₀ value of 1.43±0.26 μm and a GI₅₀ value of 0.89±0.06 μm . Notably, induction of apoptosis by 10 s on the HCT‐15 cell line was characterized by using different staining techniques, such as acridine orange/ethidium bromide (AO/EB) and DAPI. Further, to understand the mechanism of anticancer effects, various assays such as annexin V‐FITC/PI, DCFDA, and JC‐1were performed. The flow cytometric analysis revealed that compound 10 s arrests the HCT‐15 cancer cells at the G0/G1 phase of the cell cycle. Additionally, western blot analysis indicated that treatment of 10 s on HCT‐15 cancer cells led to decreased expression of anti‐apoptotic Bcl‐2 and increased protein expression of both pro‐apoptotic Bax and caspase‐3, ‐8, and ‐9, and cleaved PARP with reference to actin. Next, a clonogenic assay revealed the inhibition of colony formation in HCT‐15 cancer cells by 10 s in a dose‐dependent manner. Moreover, upon testing on normal human lung cells (HFL), the compounds were observed to be safer with a low toxicity profile. In addition, viscosity and molecular‐docking studies showed that compound 10 s has typical intercalation with DNA.     

Modulation of Mesenchymal Stem Cells for Enhanced Therapeutic Utility in Ischemic Vascular Diseases

Mesenchymal stem cells are multipotent stem cells isolated from various tissue sources, including but not limited to bone marrow, adipose, umbilical cord, and Wharton Jelly. Although cell-mediated mechanisms have been reported, the therapeutic effect of MSCs is now recognized to be primarily mediated via paracrine effects through the secretion of bioactive molecules, known as the “secretome”. The regenerative benefit of the secretome has been attributed to trophic factors and cytokines that play neuroprotective, anti-angiogenic/pro-angiogenic, anti-inflammatory, and immune-modulatory roles. The advancement of autologous MSCs therapy can be hindered when introduced back into a hostile/disease environment. Barriers include impaired endogenous MSCs function, limited post-transplantation cell viability, and altered immune-modulatory efficiency. Although secretome-based therapeutics have gained popularity, many translational hurdles, including the heterogeneity of MSCs, limited proliferation potential, and the complex nature of the secretome, have impeded the progress. This review will discuss the experimental and clinical impact of restoring the functional capabilities of MSCs prior to transplantation and the progress in secretome therapies involving extracellular vesicles. Modulation and utilization of MSCs–secretome are most likely to serve as an effective strategy for promoting their ultimate success as therapeutic modulators.